Prednisolone in Early Diffuse Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

March 4, 2021

Study Completion Date

May 27, 2021

Conditions
Systemic Sclerosis
Interventions
DRUG

Prednisolone 5 mg

5mg prednisolone, once a day for 6 months

DRUG

Placebo oral capsule; From August 2020 'no additional treatment'

Matched placebo capsule, once a day for 6 months; From August 2020 - no additional treatment above standard of care medication

Trial Locations (14)

AB25 2ZN

Aberdeen Royal Infirmary - NHS Grampian, Aberdeen

CB2 0QQ

Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge

M6 8HD

Salford Royal NHS Foundation Trust, Salford

G4 0SF

Glasgow Royal Infirmary -, Glasgow

L9 7AL

Aintree University Hospitals NHS Foundation Trust, Liverpool

NG7 2UH

Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham

BA1 1RL

Royal National Hospital For Rheumatic Diseases - Royal United Hospitals Bath NHS Foundation Trust, Bath

S10 2JF

Royal Hallamshire Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

NE7 7DN

Freeman Hospital - The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

DY1 2HQ

The Dudley Group NHS Foundation Trust, Dudley

LS7 4SA

Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds

BS10 5NB

Southmead Hospital Bristol - North Bristol NHS Trust, Bristol

DD1 9SY

Ninewells Hospital and Medical School - NHS Tayside, Dundee

NW3 2QG

Royal Free London NHS Foundation Trust, London

All Listed Sponsors
collaborator

Versus Arthritis

OTHER

lead

Prof. Ariane herrick

OTHER

NCT03708718 - Prednisolone in Early Diffuse Systemic Sclerosis | Biotech Hunter | Biotech Hunter